Efficacy and Safety of Pegcetacoplan in Adults and Adolescents with Focal Segmental Glomerulosclerosis: Phase 2/3 Open‑Label and Randomized Placebo‑Controlled Study

Registered drug

Efficacy and Safety of Pegcetacoplan in Adults and Adolescents with Focal Segmental Glomerulosclerosis: Phase 2/3 Open‑Label and Randomized Placebo‑Controlled Study

Registered drug

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Pegcetacoplan
Sponsor:Apellis Pharmaceuticals Inc.

Contact Research Centre

Ischaemic stroke

Not yet recruiting

Phase 2 Study of RADAMTS13 in Adults with Acute Ischemic Stroke

Registered drug

Phase 2 Study of RADAMTS13 in Adults with Acute Ischemic Stroke

Registered drug

France

Participants:18–64 years · 65+ years
Substances:RADAMTS13
Sponsor:Takeda Development Center Americas Inc.

Contact Research Centre

Endometrial cancer+6

Not yet recruiting

Phase 2 Study of Lirafugratinib in Patients with Previously Treated Unresectable Advanced Solid Tumors with FGFR2 Fusion (Excluding Cholangiocarcinoma)

InvestigationalNo placebo

Phase 2 Study of Lirafugratinib in Patients with Previously Treated Unresectable Advanced Solid Tumors with FGFR2 Fusion (Excluding Cholangiocarcinoma)

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Lirafugratinib hydrochloride
Sponsor:Elevar Therapeutics Inc.

Contact Research Centre

Homocystinuria

Not yet recruiting

Safety and Tolerability Study of Subcutaneous Pegtibatinase in Adults and Children with Classical Homocystinuria (Phase 1/2)

InvestigationalNo placebo

Safety and Tolerability Study of Subcutaneous Pegtibatinase in Adults and Children with Classical Homocystinuria (Phase 1/2)

InvestigationalNo placebo

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Pegtibatinase
Sponsor:Travere Therapeutics Inc.

Contact Research Centre

Allogenic stem cell transplantation+1

Not yet recruiting

Immunogenicity and safety of RSV A/B prefusion F protein vaccine versus RSV F glycoprotein recombinant adjuvanted vaccine in lung and stem cell transplant recipients

Registered drugNo placebo

Immunogenicity and safety of RSV A/B prefusion F protein vaccine versus RSV F glycoprotein recombinant adjuvanted vaccine in lung and stem cell transplant recipients

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:RESPIRATORY SYNCYTIAL VIRUS, SUBGROUP A, STABILIZED PREFUSION F PROTEIN 847A
Sponsor:Hospices Civils De Lyon

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in Saint-Cloud

What the registry says about research in the country

01 Blood Cancer Research

Innovative trials focusing on lymphoma and multiple myeloma treatments, including studies of novel therapies like duvelisib for T-cell lymphoma and odronextamab for follicular lymphoma.

B-Cell Lymphomas
Multiple Myeloma
T-Cell Lymphomas

Several studies are evaluating combination therapies and comparing new treatment approaches against standard care.

02 Breast Cancer Studies

Comprehensive research into various types of breast cancer, with particular focus on hormone receptor-positive and triple-negative variants. Studies include early detection methods and novel therapeutic combinations.

HR+/HER2- Advanced Breast Cancer
Triple-Negative Breast Cancer
Early-Stage Disease

Trials incorporate innovative approaches like ctDNA monitoring and targeted therapies.

03 Advanced Cancer Therapies

Research focusing on targeted therapies for various advanced cancers, including studies of biliary tract cancer and non-small cell lung cancer treatments.

Lung Cancer
Biliary Tract Cancer
Prostate Cancer

Emphasis on immunotherapy combinations and precision medicine approaches.

Back to France All countries